Barely Significant
← all excerpts

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.

Thorax · 2023 · PMC10314034 · PMID 35793833

Europe PMCDOI
1
hedged sentence
0.0407
closest p · 0.8× alpha
0.0407
boldest claim

The sentences

did not reach statistical significancep=0.0407actually significant
Response to lenzilumab was observed in the first through third quartiles of baseline CRP with the greatest lenzilumab treatment effect observed in the first quartile (CRP <41 mg/L; HR: 8.20; 95% CI 1.74 to 38.69; p=0.0079) and a numeric difference that did not reach statistical significance in the second quartile and a significant treatment effect observed in the third quartile (CRP 79<137 mg/L; HR: 2.25; 95% CI 1.04 to 4.88; p=0.0407 ( table 3 )).

also in 39,124 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.